Related Company:
Three teams receive awards from the Dartmouth Innovations Accelerator for Cancer
Vermont Business Magazine Three teams of Dartmouth researchers have been selected to receive the first awards from the Dartmouth Innovations Accelerator for Cancer.
A philanthropy-funded initiative, the Accelerator was launched in 2020 by Norris Cotton Cancer Center and the Magnuson Center for Entrepreneurship to bring new cancer treatments to patients more quickly. So far, it has raised $3.3 million in philanthropic gifts and seeks to hit $5 million by June. When you look at the number of biotech start-ups that have spun out of our cancer center, it s astounding, says Steven Leach, director of Dartmouth s and Dartmouth-Hitchcock s Norris Cotton Cancer Center and the Preston T. and Virginia R. Kelsey Chair in Cancer at the Geisel School of Medicine. The Accelerator builds on our culture of collaboration and innovation. In its first year, it has attracted 17 teams, including
Racial Equity Is Different From Diversity, NAIFA Members Told
Diversity is not the same as racial equity, NAIFA members were told.
Racial equity is different from diversity efforts, and Derrik Anderson told NAIFA members how and why this is so.
Anderson is executive director of Race Matters and spoke during Thursday’s portion of NAIFA’s Diversity, Equity and Inclusion Impact Week. He discussed why DEI is a critical issue for any organization and provided some practical steps on what individuals can do to advance the cause of racial equity.
Racial inequity was part of the U.S. from the beginning, he said, with government passing and enforcing laws that determined everything from who could vote to where people were permitted to live.
EVOTEC PARTNERS WITH ALLOY THERAPEUTICS TO EXPAND ITS ANTIBODY DISCOVERY PLATFORM
DGAP-News: Evotec SE / Key word(s): Miscellaneous
21.12.2020 / 07:30
EVOTEC GAINS ACCESS TO ALLOY THERAPEUTICS ATX-GX(TM) HUMANISED MICE PLATFORM FOR BIOLOGICS DISCOVERY
PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS
Hamburg, Germany, 21 December 2020:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Alloy Therapeutics ( Alloy ), a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec s antibody discovery platform.
Evotec partners with Alloy Therapeutics to expand its antibody discovery platform
Evotec partners with Alloy Therapeutics to expand its antibody discovery platform
EVOTEC GAINS ACCESS TO ALLOY THERAPEUTICS ATX-GX™ HUMANISED MICE PLATFORM FOR BIOLOGICS DISCOVERY
PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS
Hamburg, Germany, 21 December 2020:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Alloy Therapeutics ( Alloy ), a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec s antibody discovery platform.